Bio Path reported 0 in Sales Revenues for its fiscal quarter ending in March of 2025.





Sales Change Date
Alterity Therapeutics Limited AUD 596.04K 584.66K Dec/2025
Baxter International USD 2.98B 20M Sep/2026
Bio Path 0 0 Mar/2025
Cipla INR 74.04B 2.85B Sep/2026
Clal Biotechnology ILS 3.41M 2M Dec/2022
Compugen USD 2.6M 3.75M Jun/2026
CSL USD 8.33B 4.79B Dec/2025
Grifols EUR 2B 306.7M Mar/2026
Karyopharm Therapeutics USD 35.07M 987K Mar/2026